
|Videos|September 30, 2022
CHECKMATE 9ER: Quality of Life Outcomes
Author(s)Daniel J. George, MD
Dr Daniel J George talks about the quality-of-life outcomes from the CHECKMATE 9ER and how different metastatic scenarios might affect treatment selection.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































